FDA Releases Software Precertification Working Model
On April 26, 2018, the U.S. Food and Drug Administration ("FDA") released an initial working model for its Software Precertification ("Pre-Cert") Pilot Program. The Pre-Cert Program is an effort by FDA to develop a new, more streamlined regulatory framework for software as a medical device ("SaMD") developed by manufacturers who have demonstrated a robust culture of quality and organizational excellence, and who are committed to monitoring real-world performance of their products once they are introduced into the U.S. market. Under the program, manufacturers that demonstrate these qualities may qualify for either an exemption from premarket review for lower risk SaMD products, or a faster review of higher risk products.
Though details are subject to change, the working model identifies five "excellence principles" on which eligible manufacturers will be evaluated for initial precertification, which are: (i) product quality, (ii) patient safety, (iii) clinical responsibility, (iv) cybersecurity protection, and (v) proactive culture with respect to surveillance, assessment of user needs, and continuous learning. FDA has not yet settled on a mechanism for conducting precertification, but the working model envisions a voluntary application process through which a company will submit to FDA information that objectively demonstrates commitment to the above-listed principles. After initial precertification, FDA expects there to be a mechanism for monitoring and maintaining precertification status.
As has been true generally across FDA's digital health endeavors, the working model notes that FDA is actively seeking public engagement on this topic. The working model includes specific questions to the public related to various components of the model, and presents an opportunity to help shape the regulation of medical software.
Lawyer Contacts
For further information, please contact your principal Firm representative or the lawyers listed below. General email messages may be sent using our "Contact Us" form, which can be found at www.jonesday.com/contactus/.
Maureen Bennett
Boston / San Francisco
+1.617.449.6884 / +1.415.875.5772
mbennett@jonesday.com
Alexis S. Gilroy
Washington
+1.202.879.5552
agilroy@jonesday.com
Ian M. Pearson
Washington
+1.202.879.3404
ipearson@jonesday.com
Jones Day publications should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request reprint permission for any of our publications, please use our "Contact Us" form, which can be found on our website at www.jonesday.com. The mailing of this publication is not intended to create, and receipt of it does not constitute, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
